on PolyPeptide Group
PolyPeptide and Lupin Forge Strategic Alliance to Advance Peptide Supply
On December 12, 2025, PolyPeptide Group AG, a global CDMO specializing in peptide-based APIs, announced a strategic alliance with Lupin Manufacturing Solutions Limited. The collaboration aims to bolster supply chain resilience and operational efficiency to meet the rising demand for peptides in metabolic therapies.
The partnership allows PolyPeptide to diversify its sourcing options, creating a more flexible supply chain for peptide manufacturing. The agreement focuses on integrated procurement and supply planning for select raw materials, ensuring high standards of quality and reliability.
Dr. Stéphane Varray, Chief Commercial Officer of PolyPeptide, emphasized the importance of a robust supply chain in delivering life-changing therapies. Dr. Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions, highlighted the commitment to accessible, large-scale commercial production of peptide-based therapies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PolyPeptide Group news